Funds and ETFs Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 15:03:36 30/05/2024 BST 5-day change 1st Jan Change
954.3 USD -1.26% Intraday chart for Regeneron Pharmaceuticals, Inc. -2.71% +8.62%

ETFs positioned on Regeneron Pharmaceuticals, Inc.

Name Weight AuM 1st Jan change Investor Rating
7.27% 0 M€ 0.00% -
7.08% 0 M€ 0.00% -
4.02% 1 M€ 0.00% -
2.56% 8 M€ +3.41%
1.90% 17 M€ +5.88% -
1.85% 2 M€ 0.00%
1.65% 9 M€ -4.31% -
1.62% 2 M€ -25.75%
1.33% 26 M€ +16.85% -
1.13% 9 M€ +15.45% -
1.06% 0 M€ 0.00% -
1.02% 14 M€ -6.04%
1.02% 1,100 M€ +2.46%
1.01% 1 M€ +16.32%
1.00% 204 M€ +10.54%
0.94% 11 M€ -6.03% -
0.79% 9 M€ +9.06%
0.78% 265 M€ +4.16% -
0.77% 9 M€ -.--% -
0.74% 92 M€ +0.06% -
0.72% 15 M€ 0.00% -
0.72% 5 M€ -72.95% -
0.71% 3 M€ 0.00% -
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
966.5 USD
Average target price
1,042 USD
Spread / Average Target
+7.81%
Consensus
  1. Stock Market
  2. Equities
  3. REGN Stock
  4. Funds and ETFs Regeneron Pharmaceuticals, Inc.